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Influenza A virus subtype H1N1 causes severe infections in human respiratory sys-
tem. This can lead to increased risk of mortality. Neuraminidase-1 has an important role
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It is critical to seek potential alternative treatments for
H1N1 infections by inhibiting neuraminidase-1 enzyme.
One of the viable options for inhibiting the activity of neu-
raminidase-1 is peptide drug design. In order to increase
peptide stability, cyclization is necessary to prevent its
digestion by protease enzyme. Cyclization of peptide li-
gands by formation of disulfide bridges is preferable for
designing inhibitors of neuraminidase-1 because of their
high activity and specificity. Here we designed ligands by
using molecular docking, drug scan and dynamics com-
putational methods. Based on our docking results, short
polypeptides of cystein-arginine-methionine-tyrosine-
-proline-cysteine (CRMYPC) and cysteine-arginine-aspar-
gine-phenylalanine-proline-cysteine (CRNFPC) have good
residual interactions with the target and the binding en-
ergy DGbinding of –31.7402 and –31.0144 kcal mol–1, res-
pectively. These values are much lower than those of the
standards, and it means that both ligands are more ac-
cessible to ligand-receptor binding. Based on drug scan
results, both of these ligands are neither mutagenic nor
carcinogenic. They also show good oral bioavailability.
Moreover, both ligands show relatively stable molecular
dynamics progression of RMSD vs. time plot. However,
based on our metods, the CRMYPC ligand has sufficient
hydrogen bonding interactions with residues of the ac-
tive side of neuraminidase-1 and can be therefore pro-
posed as a potential inhibitor of neuraminidase-1.
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fide, molecular docking, molecular dynamics
* Correspondence; e-mail: usman@ui.ac.id
in H1N1 viral replication and acts as a major target in drug design and is one of the
serotypes of neuraminidase enzyme. However, H1N1 virus is evolving rapidly and some
drug resistance strains are emerging. H1N1 virus is a subtype of the influenza virus A,
which has become pandemic and allows the formation of a new strain that spreads from
human to human (1).
Neuraminidase has the cardinal role in viral infection, especially in its virulence.
Adaptability of influenza A virus in human populations was caused by biochemical
changes in the ability of the cell membrane attachment from a-2,3 sialic acid Gal to a-2,6
sialic acid Gal receptor (2). Influenza A virus is currently able to infect humans because
a-2,6 sialic acid Gal receptor is known as a binding agent. Influenza A virus in the in-
fected host is associated with hemagglutinin protein as an adhesive agent of the virus
for gaining entrance into the host cell and neuraminidase as an agent of the virus re-
leased from the infected host cell (3).
The important role of neuraminidase was mainly in viral replication and high con-
servation at the active site. This makes neuraminidase a key target in the design of anti-
viral influenza virus agents (4). Zanamivir and oseltamivir are antiviral drugs that can
inhibit neuraminidase processes (5). However, resistance to the antiviral oseltamivir has
increased to 98.5 % in the USA (6). To this end, it is necessary to develop a novel drug
candidate that would provide better efficacy than oseltamivir.
The design and utilization of peptides are the most promising fields in the devel-
opment of novel drugs due to their high activity and specificity, low toxicity and the fact
that they do not accumulate in the body (7–9). Almost 200 peptides are used as drugs
and approximately 400 peptides are in the preclinical phase, with an average growth of
almost 20 % for one year (10). These facts have made the peptide-based design for H1N1
drugs a viable alternative.
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Fig. 1. The pipeline of our method.
However, drug design should follow Lipinski’s rule of five in order to obtain a ro-
bust lead compound (11). According to Lipinski’s rule of five, a good drug mass should
have a molecular weight of about 500, while designed hexapeptide should have a mo-
lecular weight of 700 (12). This means that the drug candidate has a molecular mass be-
yond the designated threshold. Although it did not pass Lipinski’s rule, some peptides
have been successfully utilized as drugs. For instance, the cyclic peptide cRGD (arginine-
-glycine-aspartic acid) has been used as a therapeutic for hepatic fibrosis (13). White et
al. (14) reported that the cyclic hexapeptide of cLLLLPY (leucine-leucine-leucine-leucine-
-proline-tyrosine) has a molecular mass of 755 with three N-methyl groups; and showed
28 % oral bioavailability in rats, as the most permeable among the tested compounds.
Nowadays, peptide drug design has been assisted by the development of compu-
tational chemistry. Hence, it is important to note that computational chemistry has played
an important role in drug design with validation in wet laboratories. Docking methods
used in computational drug design can be combined with molecular dynamics simula-
tions to predict the existence of the ligand-enzyme complex. The dynamics method will
eventually give a more complete description of the biochemical reaction, by exposing its
energy state against the function of time. Antibiotic resistance is a serious problem now-
adays, and computation of DNA gyrase enzyme and its ligands has been proven in wet
labs to be correctly predicted (15). Therefore, such experiments provide strong evidence
that eventually bioinformatics tools could indeed be useful for assisting wet laboratory
experiments.
This study focuses on in silico design of cyclic hexapeptide, which is expected to in-
hibit neuraminidase-1 of influenza A virus subtype H1N1. Our method combines com-
putational chemistry, computational biology and materials science in studying molecular
systems from small chemical systems to large biological molecules (Figure 1) (16). Research
was carried out using molecular docking, drug scan and molecular dynamics.
EXPERIMENTAL
We started the experiment by searching and modeling the 3D structure of neura-
minidase-1, because a correct 3D representation of the structure is necessary for good
biochemical interaction modeling. The ligands were designed as combinations of six ami-
no acids (cyclic hexapeptide) (the pattern is available upon request as supplementary
material). The docking procedure that successfully generated data validation for osel-
tamivir and zanamivir was employed in this experiment (11). Docking was done to fit
the format file for molecular operating environment (MOE) and then geometric optimi-
zation and energy minimization were applied to have the best docking structural con-
formation. Docking analysis was done to obtain the most thermodynamically favorable
ligand-protein interaction. Drug scan was conducted to observe whether the ligand was
suitable to act as a drug or not. We obtained ligands that could be scaled as drug can-
didates. Hence, the drug candidate interaction with neuraminidase-1 must be tested based
on the durability and kinetics of the reaction. At the end, molecular dynamics analysis
was conducted to obtain the most kinetically stable ligand-protein interaction. Details of
our methodology are explained in the next subsections.
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Neuraminidase-1 sequence retrieval
Neuraminidase-1 protein sequence data with Genbank code ACT79135.1 were ob-
tained as a target enzyme for the determination of the 3D structure of H1N1 neuramini-
dase-1. Neuraminidase 3ti4B Swiss model (PDB code) was obtained as a template that had
99.23 % similarity to neuraminidase-1 {Influenza A virus [A/Japan/1070/2009 (H1N1)]}.
Neuraminidase-1 and ligand preparation
Influenza H1N1 neuraminidase-1 sequences used in this study were obtained from
the Natural Center for Biotechnology Information (NCBI) database of 2009–2011 (17, 18).
Full neuraminidase (NA) sequences were used to design the homology structure of the
online Swiss model with downloaded fast-all (FASTA) files from NCBI.
Determination of amino acid sequences was done by sequentially assigning the he-
xapeptides. Amino acid sequences of cyclic peptides could be designed and modeled
into 3D structures. The designing and modeling procedure was done using the software
of ACD labs (Advanced Chemistry Development Inc, Canada). Then, the ACD storage
format was converted into cyclic peptides using Vega zz software (Department of Phar-
maceutical Science, University of Milan, Milan, Italy) in order to facilitate the docking
process.
Molecular docking
Docking file preparation was done by optimizing the geometry, minimizing the en-
ergy of the ligand and 3D visualization of neuraminidase-1, using MOE 2008.10 software
(19). Docking process was conducted with MOE 2008.10 software. The placement me-
thod used was the triangle matcher with 1000 rounds. Scoring function used was the
London dG displaying the best data in 100 iterations. Furthermore, out of the best data,
100 measurements were repeated using the force field refinement loop configuration
with a population size of 1000 in accordance with the MOE default. From the displayed
results of the whole process, the selected data were the best ones.
Drug scan
Drug scan was performed on the drug candidates to determine whether the com-
pounds complied with Lipinski’s rule of five or not (20). Some software packages such
as ToxTree (Ideaconsult Ltd, Bulgaria), Osiris Property Explore (Actelion Pharmaceuti-
cals Ltd, Switzerland) and Free ADME-Tox Filtering tools-drug (FAF-drugs) (INSERM,
France) were used. Toxtree was used to compute the mutagenicity and carcinogenicity
properties based on compilations of stuctural alerts (21). Osiris was used to compute the
pharmacological predictions (mutagenicity, carcinogenicity, irritation, reproductive ef-
fectiveness) and drug properties (log P, solubility, drug likeness, drug score) (22). Then,
FAF Drugs 2 was used to compute Lipinski’s physical property (Mr, HBD, HBA, and log
P) and oral bioavailability based on Veber and Egan rules (23).
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Molecular dynamics simulation
Partial geometry optimization of the ligand-enzyme complex charge was done by
the current force field method, which is a 'fixed-charge' model for atomic charge value
representation that is kept stable under the influence of electrostatic fluctuation (24).
Energy minimization was then performed with a force field MMFF94x (Merck Molecular
Force Field 94x Merck Ltd., Whitehouse Station, NJ, USA). Root mean square (RMS) is a
measure of the size of distribution given to electronic gradient during minimization.
Zero gradient is the optimized energy. The utilized solvation is born with RMS of 0.05
gradient kcal mol Å. Default parameters of the dynamics simulation were employed and
the simulation output files are in MOE (Chemical Computing Group, Canada) format
for dynamics simulation (25).
Molecular dynamics simulation of the ligand inhibitor was performed by MOE-
2008.10 MOE-dynamics. The parameters were used in accordance with the MOE-default
for the dynamics NVT ensemble (N – number of atoms; V – volume, T – temperature)
with the NPA (Nosé-Poincaré-Andersen) algorithm (26). Timing of conformational sta-
bility of the enzyme complex to solvents was performed for 100 ps at the equilibration
stage. Simulations were performed at 5000 ps, temperatures of 310 K (the conditions of
normal human body temperature) and 312 K (the temperature conditions of fever in
humans).
RESULTS AND DISCUSSION
Although MOE 2008.10 is a reliable and cost-effective program, there is one caveat
that should be considered. Docking involving standard stochastic search conditions was
not efficient and applicable for the high-throughput mode (27). From the modeling re-
sults, Qualitative model energy analysis 4 (QMEAN4) score of 0.66 was obtained. This
value is still within the allowable range for the reliability of models, estimated between
0–1.
To determine the quality of the modeled structure, it was analyzed using the Rama-
chandran plot (28) (Fig. 2). This infers that there are no residues at all in the disallowed
region. Results of the structural analysis of neuraminidase-1 show that there is a single
amino acid residue in the disallowed region or approximately 0.3 % of total residues.
When more than 15 % of non-glycine residues are located in disallowed regions, it can
be concluded that the structure of the proteins has very bad quality (very unstable), so it
can be inferred that the structure of the model is of good quality and can be used for
further analysis.
The information on amino acid residues in the neuraminidase-1 active site can be
seen in NCBI data. H1N1 neuraminidase-1 ACT79135.1 has seven functional amino acids
that play a role in active sites. They are Arg118, Asp151, Glu278, Arg293, Arg368, Tyr402
and Glu425.
Elucidation of the amino acid sequences of peptides inhibitors is based on the pro-
perties of the amino acid residues of the H1N1 neuraminidase-1 (11). The neuramini-
dase-1 enzyme has four amino acid residues that play a role in the active site, which has
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positive and negative properties of polar charge. Neuraminidase-1 binding sites exist
around Glu119, Arg152, Arg156, Trp179, Ser180, Ile223, Arg225, Glu228, Ser247, Tyr274,
Glu277 and Asn295. They are polar and non-polar residues. Therefore, the cyclic peptide
ligand was formed by combining four amino acids with polar and non-polar groups,
and on their edges there were two cystein residues that formed a bond connecting them.
The combination of 11 polar amino acid residues (aspartic acid, asparagine, serine,
trionin, glutamine, glutamic acid, lysine, histidine, tyrosine, cysteine and arginine) and
nine non-polar amino acid residues (alanine, glycine, valine, leucine, isoleucine, triptho-
pan, phenylalanine, methionine and proline) produced 5096 cyclic hexapeptide ligands.
The utilized standard ligands were oseltamivir, zanamivir, AD3BF2D and NNY.
File preparation and docking were done with energy minimization to optimize the
geometry of 3D structure of neuraminidase-ligands and it was expected to eliminate un-
desirable interactions in the structure (bad contact) of protein structure (19). Thus, ener-
gy minimization was necessary to fix conformational problems associated with X-ray or
NMR-based structures.
Molecular docking was designed to search for the proper conformation of the bond
between ligand and receptor. The process was carried out on 5096 ligands and four stan-
dard ligands (zanamivir, oseltamivir, AD3BF2D, and NNY). In molecular docking, the
enzyme was made rigid and the ligand on the left was flexible, so that it could freely
move and rotate. The docking based-screening was performed three times, and the first
screening resulted in 200 ligands that had the lowest binding free energy value. It was
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Fig. 2. Ramacandran plot of
the modeled neuraminidase
structure. The f and Y angels
in the polypeptides, shown
in the plot refer to the poly-
peptide backbone rotations in
the bond between N-Ca (f)
and Ca-C (Y).
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Table I. Free binding energy values (DG) of molecular docking results
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computed under thermodynamically equilibrium conditions. The value of DG binding
described the binding strength of enzyme and ligand. Out of the 200 best ligands, which
were repeated, 15 were obtained with the lowest Gibbs energy. The docking results are
seen in Table I.
Among the fifteen ligands selected based on the lowest DGbinding value, several did
not have the properties of carcinogens and mutagens. In the design process of the anti-
viral compound, ADMET (absorption, distribution, metabolism, excretion and toxicity)
should be considered as an important step. Those properties were detected using the
software ToxTree, Osiris Property Explore and FAF-drugs (23).
From the screening results using Toxtree software, it can be inferred that the fifteen
ligands do not have mutagenic and carcinogenic properties. The screening results were
obtained using the software Osiris Property Explore. It showed that ligands CRWHVC,
CCMSWC and CRYLWC are mutagenic. CRWHVC ligand also has the potential to be
tumorigenic, while the standard ligand oseltamivir possesses tumorigenic and mutagen-
ic potential, which is less than that of the three ligands above. In addition to the four
ligands, all ligands lack mutagenic and tumorigenic potential, irritation but have parti-
cularly effective reproductive values. Judging from the value of drug-likeness, simila-
rities are observed within the properties of the existing drugs, because only two ligands
have a good value compared to zanamivir, the standard ligand, namely CRMYPC and
CRNFPC.
The main properties were screened by FAF-drugs including total H-bonds, tPSA (to-
pological polar surface area) value, rotatable bonds, and log P (23). From the software
FAF-drugs, CRMYPC and CRNFPC showed good bioavailability. However, CRMYPC
had unfavorable bioavailability compared to CRNFPC.
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CRMYPC and CRNFPC form fifteen and thirteen hydrogen bonds with the whole
neuraminidase-1 amino acid residues, respectively, while the standard ligands, namely
AD3BF2D, NNY, oseltamivir and zanamivir have six, eight, three and eight hydrogen
bonds, respectively. CRMYPC and CRNFPC have formed seven and eight hydrogen
bonds with active site residue of neuraminidase-1, respectively, while AD3BF2D, NNY
and zanamivir have three, three and four hydrogen bonds, respectively. Although the
standards have much less hydrogen bonding than our ligands, they could still perform
as drugs. We argue that stronger hydrogen bonding in our ligands will eventually pro-
duce a more robust ligand-receptor interaction. The results of DGbinding for both CRMYPC
and CRNFPC were more negative than that of the standard ligands. Oseltamivir and
other standard ligands have not formed hydrogen bonding with the active site residue
of neuraminidase-1 because of the mutation in the neuraminidase-1 amino acid residues.
This indicates that neuraminidase-1 is resistant to oseltamivir.
Interaction between the ligand and CRNFPC and CRMYPC is seen in Figs. 3a and b.
CRMYPC and CRNFPC ligand conformations cover and fill the cavity of neuramini-
dase-1, so that these enzyme binding site ligands are proposed to act as competitive in-
hibitors. The potential binding site ligands bind to the enzyme and interfere with the
catalytic activity of the enzyme.
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Fig. 3. a) The interaction of CRMYPC ligand with neuraminidase, b) the interaction of CRNFPC
ligand with neuraminidase (MOE 2008.10).
CRMYPC interaction with neuraminidase-1 shows some of the interactions between
amino acid residues in the active site of neuraminidase-1 with the ligand through hyd-
rogen bonding. It happens, among others, with Asp151, Arg293 and Arg368 side chains
that occur with arginine (amino acid code: R). Moreover, the interactions of residues
Asp151 with cysteine (amino acid code: C) backbone could be observed as well.
CRNFPC ligand interacts with neuraminidase-1 through different hydrogen bonds
than ligand CRMYPC. Amino acid residues in the active site of neuraminidase-1 that
show hydrogen-bonding interaction are Asp151, Glu278 and Arg293 in the side chain of
cysteine (C) and arginine (R).
Molecular dynamics was employed to study the effect of the presence of an explicit
solvent system to explore the conformation of the receptor protein.
In a solution, protein is a dynamic molecule that does not have a single conforma-
tion. Conformational change of the enzyme-ligand complex can be seen from the full
root mean square deviation (RMSD) vs. time simulation.
From Fig. 4, it is seen that the conformation of the ligand-enzyme complex at the
beginning of the simulation (duration of 0–100 ps) is very volatile due to exponential
climb of the energy function, and the simulation time is quite stable beyond 100 ps. The
patterns in the graph that tend to be linear demonstrate this trend. Changes in the curve
at the beginning of the simulation (0–100 ps) occur for both complexes, CRMYPC and
CRNFPC, with considerable fluctuations. This indicates that the conformational changes
of the structure of the ligand-enzyme complex are large enough during that time span.
During the time of 100 ps, the simulation shows that the curve becomes linear. It sug-
gests that, in this time span, the conformation of ligand-enzyme complex structure does
not change significantly.
Increasing the temperature will result in increased movement of proteins. However,
it can not be inferred whether the interactions between the protein and ligand become
unstable. This is demonstrated by the insignificant increase in the RMSD value. The
CRMYPC-enzyme complex undergoes an insignificant conformational change during
the rising temperature. This ligand is slightly more reactive at temperatures of 312 K
(fever body temperature) compared to 310 K temperature (normal body temperature), as
can be seen from the tiny change in the value of RMSD. However, the CRNFPC-enzyme
complex RMSD values at 300 and 312 K do not vary that much.
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Fig. 4. RMSD vs. simulation time for: a) CRMYPC ligand, b) CRNFPC ligand.
Differences in RMSD vs. timeplots that occur in CRMYPC-enzyme complex at tem-
peratures of 310 K and 312 K seem noticeable compared to the curve in the CRNFPC-
-enzyme complex (Fig. 4). These changes can be attributed to the stability of the complex
formation. CRMYPC sequences are composed of polar-polar-non-polar-polar-non-polar-
-polar residues, which are slightly more stable at temperatures below 310 K. However,
the CRNFPC sequences are composed of polar-polar-non-polar-polar-non-polar-polar
residues. Hence, we argue that the curve differences will not affect the total stability of
the complex due to the linear curves trend (Fig. 3a). Due to constant stability of the
structure, the curve difference is totally negligible.
The stability of protein and ligand could be seen from the correlation plot between
the total potential energy of the system during simulation. Decrease of the total potential
energy system from three protein-ligand complex during simulation is an indication of a
stable system. This can be seen from the amount of interactions that occur at the enzyme-
-binding site of both CRMYPC and CRNFPC.
The time-dependent distance graphs for CRMYPC and CRNFPC ligands at 310 and
312 K have shown that the distance fluctuations in the ligand-receptor complex are attri-
buted to the Brownian motion (29) (Fig. 5).
The toxicity data of our designed ligands and the standards can be found in the
supplementary material (available upon request). However, as we sum up the data into
Table I, it can be seen that most of our designed ligands have no observable malignant
effects. Hence, most of them are not in accord with Lipinski’s rules. However, based
upon our docking and dynamics results, these ligands could still be utilized as drug can-
didates.
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CRMYPC Ligand CRNFPC Ligand
310 K a)
b)
312 K c) d)
Fig. 5. The time-dependent distance graph for CRMYPC and CRNFPC ligands at 310 and 312 K.
Axis x depicts the time function, while axis y depicts the position function.
CONCLUSIONS
Based on the simulation results of molecular docking and drug scan, there are two
ligands that have good values of the residue target interaction and toxicological proper-
ties. These ligands are CRMYPC and CRNFPC. Both ligands have DGbinding values of
–31.7402 and 31.0144 kcal mol–1, they are not mutagenic and carcinogenic and have good
oral bioavailability.
Based on the evaluation of molecular dynamics simulations of the ligand in the
hydrated state, CRMYPC ligand has hydrogen-bonding interactions with residues of the
active site of neuraminidase-1. At the temperature of 310 K, it formed a hydrogen bond
with Arg368, Tyr402, Glu425, while at 312 K, it formed a hydrogen bond with Asp151.
Differences in enzyme conformation during the simulation show the effect of tempera-
ture on enzyme activity. The results above indicate that the CRMYPC ligand can be used
as neuraminidase-1 inhibitor candidate against the influenza virus A H1N1.
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Table II. The Utilization of ADME-TOX softwares (Toxtree, Osiris, and FAF2) toward the ligands










CRWHVC – High mutagenicity, mild
tumorigenicity
CCMSWC – High mutagenicity








AD3BF2Da Positive for genotoxic
carcinogenicity
irritant –
NNYa – – –
Zanamivira – – –
Oseltamivira Mild tumorigenic and mutagenic –
a Standard
– No observable malignant effect.
In order to prove the efficacy of the ligand, wet laboratory experiments of in vitro
and in vivo methods should be utilized. In this way, the drug candidate will be prepared
for the clinical trial process.
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